{"id":"W2192931230","doi":"10.1158/1078-0432.ccr-15-1221","title":"A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Response Evaluation Criteria in Solid Tumors; Peripheral edema; Pharmacodynamics; Adverse effect; Internal medicine; Angiopoietin receptor; Gastroenterology; Refractory (planetary science); Antibody; Pharmacology; Toxicity; Oncology; Angiogenesis; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001719639,0.0002363156,0.0005932693,0.0002065433,0.0001160419,0.00002299624,0.0005419403,0.0001913898,0.00005015801],"category_scores_gemma":[0.0001980683,0.0001994836,0.0001326203,0.0004448331,0.0003797265,0.00001432003,0.0003606988,0.0004102331,0.000004069781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001055121,"about_ca_system_score_gemma":0.0004474884,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001180508,"about_ca_topic_score_gemma":0.004306563,"domain_scores_codex":[0.9964784,0.0004070972,0.0008991081,0.0008137428,0.0007563584,0.0006452433],"domain_scores_gemma":[0.9981776,0.00006234375,0.0002058705,0.0006391234,0.0006512417,0.0002637973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003039982,0.00744923,0.9791693,0.00004800903,0.00008643072,0.00003776452,0.000301696,0.0003086765,0.006401856,0.00001103867,0.0009327053,0.002213307],"study_design_scores_gemma":[0.04147217,0.02813943,0.9195893,0.0003133134,0.00002964124,0.000001182035,0.001066383,0.00005762092,0.006102565,0.00005782628,0.002637872,0.0005326781],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977778,0.000803137,0.00000762904,0.00008326658,0.00008829003,0.0009821201,0.00003901129,0.000007416465,0.0002113968],"genre_scores_gemma":[0.9990215,0.0001214777,0.00004735359,0.00004450651,0.0002380836,0.0002123525,0.0001059092,0.00004839375,0.0001604327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05957999,"threshold_uncertainty_score":0.8134707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1156749515187689,"score_gpt":0.5107361207049393,"score_spread":0.3950611691861704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}